Please login to the form below

Not currently logged in
Email:
Password:

Valeant acquires AB Sanitas

Canada-based Valeant Pharmaceuticals International is to acquire Lithuanian speciality pharmaceutical company AB Sanitas in a two-stage deal worth €314m

Canada-based Valeant Pharmaceuticals International is to acquire Lithuanian speciality pharmaceutical company AB Sanitas in a two-stage deal worth €314m.

AB Sanitas sells about 390 generic products in nine Central and Eastern European countries. Its largest markets are Poland, Russia and Lithuania.

Valeant said the major shareholders of AB Sanitas have agreed to sell an 87 per cent stake in the company. That portion of the deal is expected to close during the third quarter, and Valeant said it will then start an offer for the remaining shares.

The Ontario-based company expects to assume €50m ($70.3m) in debt as part of the deal. The acquisition is expected to close during the fourth quarter of 2011.

AB Sanitas is based in Kaunas and develops its own dermatology, ophthalmology and hospital injectable drugs.

26th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...
Spotlight interview: 15 minutes on Independent Medical Education
Celeste Kolanko, Managing Director of Liberum, OPEN Health takes 15 minutes to answer some key questions on independent medical education....

Infographics